Table 4. Univariable and Multivariable Cox Regression Analyses of Factors Associated With Disease-Free Survival in the Matched Data Sets of Patients With AC vs Patients With MANEC.
| Clinicopathological features | Analysis | |||||
|---|---|---|---|---|---|---|
| Univariable | Multivariable Ia | Multivariable IIb | ||||
| HR (95% CI) | P value | HR (95% CI)c | P value | HR (95% CI)c | P value | |
| Age | 1.02 (1.01-1.03) | <.001 | 1.02 (1.01-1.03) | <.001 | 1.02 (1.01-1.03) | <.001 |
| Sex | ||||||
| Men | 1 [Reference] | .31 | NA | NA | NA | NA |
| Women | 0.91 (0.76-1.09) | NA | NA | NA | NA | |
| Center volume | ||||||
| Low | 1 [Reference] | .049 | NA | .27 | NA | .26 |
| High | 0.56 (0.32-1.00) | NA | NA | |||
| Location | ||||||
| Lower | 1 [Reference] | NA | NA | NA | NA | NA |
| Middle | 1.06 (0.87-1.30) | .58 | NA | .12 | NA | .11 |
| Upper | 1.24 (1.04-1.47) | .02 | NA | .45 | NA | .43 |
| Mix | 1.70 (1.36-2.12) | <.001 | NA | .31 | NA | .49 |
| Tumor size, per 1-cm increase | 1.15 (1.12-1.18) | <.001 | NA | .05 | 1.03 (1.00-1.06) | .05 |
| Lymph nodes examined, per 1-cm increase | 1.00 (1.00-1.01) | .62 | NA | NA | NA | NA |
| No. of metastatic lymph nodes, per 1-unit increase | 1.06 (1.06-1.07) | <.001 | 1.05 (1.04-1.06) | <.001 | 1.05 (1.04-1.06) | <.001 |
| Invasion | ||||||
| Vascular | 1.74 (1.51-2.01) | <.001 | NA | .51 | NA | .52 |
| Neural | 1.83 (1.58-2.12) | <.001 | 1.26 (1.09-1.47) | .002 | 1.28 (1.10-1.49) | .001 |
| T stage | ||||||
| T1-T2 | 1 [Reference] | <.001 | 1 [Reference] | <.001 | 1 [Reference] | <.001 |
| T3-T4 | 4.47 (3.43-5.83) | 2.62 (1.98-3.48) | 2.48 (1.86-3.31) | |||
| N stage | ||||||
| N0 | 1 [Reference] | <.001 | 1 [Reference] | <.001 | 1 [Reference] | <.001 |
| N1-N3 | 3.33 (2.67-4.16) | 1.58 (1.24-2.01) | 1.56 (1.23-1.99) | |||
| Type of gastrectomy | ||||||
| Total | 1 [Reference] | <.001 | NA | .54 | NA | .32 |
| Subtotal | 0.75 (0.65-0.87) | NA | NA | |||
| Received neoadjuvant chemotherapy | ||||||
| No | 1 [Reference] | .003 | 1 [Reference] | .003 | NA | NA |
| Yes | 1.90 (1.25-2.87) | 1.86 (1.23-2.83) | NA | NA | ||
| Received adjuvant chemotherapy | ||||||
| No | 1 [Reference] | NA | NA | NA | NA | NA |
| Yes | 1.117 (0.968-1.286) | .13 | NA | NA | NA | NA |
| Unknown | 0.987 (0.529-1.244) | .89 | NA | NA | NA | NA |
| Pathological type I | ||||||
| AC | 1 [Reference] | .02 | 1 [Reference] | .01 | NA | NA |
| MANEC | 1.21 (1.03-1.43) | 1.25 (1.05-1.49) | NA | NA | ||
| Pathological type II | ||||||
| Poorly differentiated AC | 1 [Reference] | NA | NA | NA | 1 [Reference] | NA |
| Well or moderately differentiated AC | 0.73 (0.62-0.86) | <.001 | NA | NA | 1.07 (0.90-1.27) | .47 |
| MANEC | 1.05 (0.88-1.25) | .59 | NA | NA | 1.27 (1.06-1.54) | .01 |
Abbreviations: AC, adenocarcinoma; HR, hazard ratio; MANEC, mixed adenoneuroendocrine carcinoma; NA, not applicable.
a
Multivariate Analysis I included pathological type I, excluding pathological type II.
b
Multivariate Analysis II included pathological type II, excluding pathological type I.
c
Because multivariate analyses used a forward likelihood ratio method, there are no corresponding HR data for factors with P > .05.